logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

CML-CP/CML-AP: promising responses seen with distinctly different TKI asciminib

7 in 10 patients had failed more than or equal to 3 prior TKIs.